Get the Stockscreener App
92.00
6.24%
5.40
Celcuity Inc stock is traded at $92.00, with a volume of 1.33M.
It is up +6.24% in the last 24 hours and down -17.15% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$86.60
Open:
$83.04
24h Volume:
1.33M
Relative Volume:
0.87
Market Cap:
$4.49B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-23.60
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
-0.84%
1M Performance:
-17.15%
6M Performance:
-11.97%
1Y Performance:
+77.30%
1-Day Range:
$83.04
$95.56
1-Week Range:
$83.04
$95.56
52-Week Range:
$44.42
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
92.00 | 4.49B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Celcuity (CELC) Q2 2026 Ergebniskonferenz: REVTORPYK-Markteinführung für Ende Q3 geplant - tradingkey.com
Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings - MarketBeat
Celcuity remains a Buy as FDA approval and stro... - Pluang
Stifel cuts Celcuity stock price target on refined market model - Investing.com
Celcuity (NASDAQ:CELC) Given New $140.00 Price Target at Needham & Company LLC - MarketBeat
Celcuity: REVTORPYK Is Now A Commercial Story (NASDAQ:CELC) - Seeking Alpha
Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus - MarketBeat
Celcuity Analysts Slash Their Forecasts After Q2 Loss - benzinga.com
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside - TradingView
Needham cuts Celcuity stock price target on updated revenue model - Investing.com
Celcuity Inc. Stock 12‑Month Price Target Cut to $162.18, Implies 87% Upside - TradingView
Celcuity Q2 Net Loss Widens to $73.6M as R&D Spending Rises - minichart.com.sg
CELC SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Celcuity Q2 Adjusted Loss Widens - Moomoo
Celcuity Q2 2026 Earnings Call Transcript - MarketBeat
CELC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Celcuity Inc. - ACCESS Newswire
CELCUITY INC. : NEEDHAM CUTS TARGET PRICE TO $140 FROM $157 - Bitget
Celcuity Q2 Earnings Call Highlights - MarketBeat
CELCUITY ($CELC) Releases Q2 2026 Earnings - quiverquant.com
CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch - TradingView
Celcuity Inc. (CELC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celcuity Reports Q2 2026 Form 10-Q Highlighting FDA-Approved REVTORPYK and Ongoing Clinical Trials - Kalkine Media
Celcuity Q2 Results: Net Loss Widens To $78.9 Million Amid Launch Prep - scanx.trade
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript - benzinga.com
Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts - Stock Titan
Celcuity Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Celcuity beats second quarter loss estimates By Investing.com - Investing.com South Africa
Celcuity beats second quarter loss estimates - Investing.com
Celcuity posts narrower-than-expected loss as R&D costs decreased - TradingView
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12 - marketscreener.com
Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celcuity earnings loom as breast cancer drug approval fuels optimism By Investing.com - Investing.com Canada
Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC - MarketBeat
Bank of America Corp DE Sells 262,789 Shares of Celcuity, Inc. $CELC - MarketBeat
Assenagon Asset Management S.A. Buys New Shares in Celcuity, Inc. $CELC - MarketBeat
Understanding the Setup: (CELC) and Scalable Risk - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Cuts Stake in Celcuity, Inc. $CELC - MarketBeat
Celcuity (CELC.US) will release its earnings report after market close on August 13. - Moomoo
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity faces investigation after FDA approval delays cause stock to drop 17.6%. - Pluang
Celcuity Inc. (CELC) stock price, news, quote and history - Yahoo Finance Australia
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call - GlobeNewswire
Celcuity (CELC) Expected to Announce Earnings on Thursday - MarketBeat
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):